Sugi Predict

Sugi Predict / Compounds / SCHEMBL5322017

SCHEMBL5322017

SCHEMBL5322017

NC(Cc1ccc2[nH]ccc2c1)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 4/20 0.54
▸ PTGS1 P23219 2/20 0.54
▸ PTGS2 P35354 2/20 0.54
▸ KDM4E B2RXH2 2/20 0.54
▸ ADORA3 P0DMS8 2/20 0.54
▸ ALOX15 P16050 2/20 0.54
▸ HTR2A P28223 2/20 0.54
▸ HSD17B10 Q99714 2/20 0.54
▸ USP2 O75604 1/20 0.54
▸ EGFR P00533 1/20 0.54
▸ LCK P06239 1/20 0.54
▸ FYN P06241 1/20 0.54
▸ RECQL P46063 1/20 0.54
▸ HIF1A Q16665 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ PKM P14618 2/20 0.49
▸ ALPI P09923 1/20 0.49
▸ XIAP P98170 1/20 0.49
▸ HDAC1 Q13547 1/20 0.46
▸ HDAC8 Q9BY41 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31370039 1.00 SLC7A5 (0.54) SLC7A5PTGS1PTGS2KDM4EADORA3
SCHEMBL21219821 1.00 SLC7A5 (0.54) SLC7A5PTGS1PTGS2KDM4EADORA3
SCHEMBL29981560 1.00 SLC7A5 (0.54) SLC7A5PTGS1PTGS2KDM4EADORA3
SCHEMBL31369576 0.89 PTGS2 (0.58) SLC7A5PTGS1PTGS2KDM4EADORA3
SCHEMBL5321639 0.88 SLC7A5 (0.54) SLC7A5PTGS1PTGS2KDM4EADORA3
SCHEMBL26008228 0.88 SLC7A5 (0.54) SLC7A5PTGS1PTGS2KDM4EADORA3
SCHEMBL5326892 0.85 GRIK1 (0.60) SLC7A5PTGS1PTGS2KDM4EADORA3
Levodopa SCHEMBL9398162 0.84 SLC7A5 (0.69) SLC7A5PTGS1PTGS2KDM4EADORA3
Levodopa SCHEMBL9398165 0.84 SLC7A5 (0.69) SLC7A5PTGS1PTGS2KDM4EADORA3
SCHEMBL16228614 0.83 TAS1R3 (0.49) HDAC1HDAC8ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118201966-A Human transferrin receptor binding antibody-peptide conjugates 肽梦想株式会社 2024-06-14 — — CN disclosed
US-11723945-B2 Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions TEMPLE OTORONGO LLC (US) 2023-08-15 — — US disclosed
CN-115151556-A Human transferrin receptor binding peptides JCR制药股份有限公司 2022-10-04 — — CN disclosed
EP-4013440-A1 THERAPEUTIC PEPTIDES Cohbar Inc. (US) 2022-06-22 — — EP disclosed
EP-3917944-A1 THERAPEUTIC PEPTIDES Cohbar Inc. (US) 2021-12-08 — — EP disclosed
US-11078233-B2 Tripeptide epoxy ketone protease inhibitors ONYX THERAPEUTICS, INC. (US) 2021-08-03 — — US disclosed
WO-2021030687-A1 THERAPEUTIC PEPTIDES COHBAR, INC. (US) 2021-02-18 — — WO disclosed
WO-2020160003-A1 THERAPEUTIC PEPTIDES COHBAR, INC. (US) 2020-08-06 — — WO disclosed
US-20200207809-A1 TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS ONYX THERAPEUTICS, INC. 2020-07-02 — — US disclosed
US-10647744-B2 Tripeptide epoxy ketone protease inhibitors ONYX THERAPEUTICS, INC. (US) 2020-05-12 — — US disclosed
US-20190241615-A1 CYCLIC PEPTIDE INHIBITORS OF HEDGEHOG PROTEINS UNIVERSITY OF ROCHESTER 2019-08-08 — — US disclosed
US-RE47302-E1 Peptide epoxyketone immunoproteasome inhibitors ONYX THERAPEUTICS INC. (US) 2019-03-19 — — US disclosed
EP-2970224-B1 TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS ONYX THERAPEUTICS INC (US) 2017-09-06 — — EP disclosed
US-20160368946-A1 TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS ONYX THERAPEUTICS, INC. 2016-12-22 — — US disclosed
US-9434761-B2 Tripeptide epoxy ketone protease inhibitors ONYX THERAPEUTICS, INC. (US) 2016-09-06 — — US disclosed
US-20140336106-A1 TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS ONYX THERAPEUTICS, INC. (US) 2014-11-13 — — US disclosed
US-20070258899-A1 Diagnostic and therapeutic agents KARYON-CTT LTD (FI) 2007-11-08 — — US disclosed
WO-2007113385-A1 DIAGNOSTIC AND THERAPEUTIC AGENTS KARYON-CTT LTD (FI) 2007-10-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190241615-A1 CYCLIC PEPTIDE INHIBITORS OF HEDGEHOG PROTEINS SHH, SMO, DACH1 SLC7A5 3485/4885PTGS1 1101/4885PTGS2 2037/4885
US-11078233-B2 Tripeptide epoxy ketone protease inhibitors PREP, CTRL, ENPEP SLC7A5 3859/4885PTGS1 189/4885PTGS2 485/4885
US-20200207809-A1 TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS PREP, CTRL, ENPEP SLC7A5 3859/4885PTGS1 189/4885PTGS2 485/4885
US-20160368946-A1 TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS PREP, CTRL, ENPEP SLC7A5 3859/4885PTGS1 189/4885PTGS2 485/4885
US-20140336106-A1 TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS PREP, CTRL, ENPEP SLC7A5 3859/4885PTGS1 189/4885PTGS2 485/4885
US-10647744-B2 Tripeptide epoxy ketone protease inhibitors PREP, CTRL, ENPEP SLC7A5 3859/4885PTGS1 189/4885PTGS2 485/4885
US-20070258899-A1 Diagnostic and therapeutic agents YBX1, MLX, TPX2 SLC7A5 3712/4885PTGS1 1844/4885PTGS2 2672/4885
US-11723945-B2 Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions TPH1, TPH2, SYMPK SLC7A5 2051/4885PTGS1 540/4885PTGS2 769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.